Eficacia comparada de la hidroxiurea y la anagrelida | 21 JUN 06

Trombocitemia esencial con alto riesgo de eventos vasculares

Estudio comparativo del United Kingdom Medical Research Council Primary Thrombocythemia 1 en 809 pacientes.
Autor/a: Dres. CL. Harrison, PJ. Campbell, G. Buck, K. Wheatley Fuente: Comentario y resumen objetivo: Dra. Marta Papponetti NEJM 353 (1), 2005
INDICE:  1. Desarrollo | 2. Bibliografía
Bibliografía
1. Tefferi A, Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Rev 2001;15:121-131. 

2. Barbui T. Indications for lowering platelet numbers in essential thrombocythemia. Semin Hematol 2003;40:Suppl 1:22-25.

3. Harrison CN, Green AR. Essential thrombocythemia. Hematol Oncol Clin North Am 2003;17:1175-1190. 

4. Spivak JL, Barosi G, Tognoni G, et al. Chronic myeloproliferative disorders. Hematology (Am Soc Hematol Educ Program) 2003:200-24.

5. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990;8:556-562. 

6. Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 1999;13:150-154. 

7. Jantunen R, Juvonen E, Ikkala E, Oksanen K, Anttila P, Ruutu T. The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia. Ann Hematol 2001;80:74-78. 

8. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-1136. 

9. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000;110:577-583. 

10. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998;91:616-622. 

11. Silverstein MN, Petitt RM, Solberg LA Jr, Fleming JS, Knight RC, Schacter LP. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med 1988;318:1292-1294. 

12. Abe Andes W, Noveck RJ, Fleming JS. Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers. Thromb Haemost 1984;52:325-328. 

13. Mazur EM, Rosmarin AG, Sohl PA, Newton JL, Narendran A. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 1992;79:1931-1937. 

14. Solberg LA Jr, Tefferi A, Oles KJ, et al. The effects of anagrelide on human megakaryocytopoiesis. Br J Haematol 1997;99:174-180. 

15. Tomer A. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood 2002;99:1602-1609. 

16. Tang SS, Frojmovic MM. Inhibition of platelet function by antithrombotic agents which selectively inhibit low-Km cyclic 3',5'-adenosine monophosphate phosphodiesterase. J Lab Clin Med 1980;95:241-257. 

17. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and
leukemic transition by treatment. Semin Hematol 1997;34:29-39. 

18. Cannon CP, McCabe CH, Wilcox RG, et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000;102:149-156. 

19. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-124. 

20. Barosi G, Ambrosetti A, Finelli C, et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol 1999;104:730-737. 

21. Bain BJ, Clark DM, Lampert IA, Wilkins BS. Bone marrow pathology. 3rd ed. London: Blackwell Science, 2001.

22. Brunning RD, Matutes E, Harris NL, et al. Acute myeloid leukaemias. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and genetics of tumours of haemopoietic and lymphoid tissues. Vol. 3 of World Health Organization classification of tumours. Lyon, France: IARC Press, 2001:75-107.

23. Brunning RD, Bennett JM, Flandrin G, et al. Myelodysplastic syndromes. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and genetics of tumours of haemopoietic and lymphoid tissues. Vol. 3 of World Health Organization classification of tumours. Lyon, France: IARC Press, 2001:61-73.

24. Pearson TC. Evaluation of diagnostic criteria in polycythemia vera. Semin Hematol 2001;38:Suppl 2:21-24. 

25. White SJ, Freedman LS. Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer 1978;37:849-857. 

26. Ellenberg SS, Fleming TR, DeMets DL. Data monitoring committees in clinical trials: a practical perspective. Chichester, England: John Wiley, 2002.

27. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Control Clin Trials 1984;5:348-361. 

28. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39. 

29. Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer. Vol. 1. Worldwide evidence 1985-1990. Oxford, England: Oxford University Press, 1990:6-9, 12-8.

30. Bouchard BA, Tracy PB. Platelets, leukocytes, and coagulation. Curr Opin Hematol 2001;8:263-269. 

31. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000;96:4261-4266. 

32. Brun M, Bourdoulous S, Couraud PO, Elion J, Krishnamoorthy R, Lapoumeroulie C. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. Pharmacogenomics J 2003;3:215-226. 

33. Nahavandi M, Tavakkoli F, Wyche MQ, Perlin E, Winter WP, Castro O. Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea. Br J Haematol 2002;119:855-857. 

34. Fleming JS, Buyniski JP. A potent new inhibitor of platelet aggregation and experimental thrombosis, anagrelide (BL-4162A). Thromb Res 1979;15:373-388. 

35. Bellucci S, Legrand C, Boval B, Drouet L, Caen J. Studies of platelet volume, chemistry and function in patients with essential thrombocythaemia treated with anagrelide. Br J Haematol 1999;104:886-892. 

36. Cacciola RR, Francesco ED, Giustolisi R, Cacciola E. Effects of anagrelide on platelet factor 4 and vascular endothelial growth factor levels in patients with essential thrombocythemia. Br J Haematol 2004;126:885-886. 

37. Lofvenberg E, Wahlin A, Roos G, Ost A. Reversal of myelofibrosis by hydroxyurea. Eur J Haematol 1990;44:33-38. 

38. Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukaemia: a comparative retrospective multicentre histological and clinical study. Br J Haematol 2000;108:64-71. 
 

Comentarios

Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí

Contenidos relacionados
Los editores le recomiendan continuar con las siguientes lecturas:
AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2020